OTC Pharmaceuticals in Hungary
Published: August 2013 · Publisher: MarketLine
OTC Pharmaceuticals in Hungary industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017).
- Description
- Companies Mentioned
- Table of Contents
- Ask a Question
Introduction
OTC Pharmaceuticals in Hungary industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Hungary otc pharmaceuticals market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other analgesics), and medicated skin products (anti-bacteria’s, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2012 annual average exchange rates.
*The Hungarian OTC pharmaceuticals market had total revenues of $482.3m in 2012, representing a compound annual growth rate (CAGR) of 3.2% between 2008 and 2012.
*The traditional medicines segment was the market's most lucrative in 2012, with total revenues of $188.0m, equivalent to 39% of the market's overall value.
*The performance of the market is forecast to follow the similar pattern with an anticipated CARC of 3.2% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $565.5m by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the otc pharmaceuticals market in Hungary
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the otc pharmaceuticals market in Hungary
Leading company profiles reveal details of key otc pharmaceuticals market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Hungary otc pharmaceuticals market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the Hungary economy
Key Questions Answered
What was the size of the Hungary otc pharmaceuticals market by value in 2012?
What will be the size of the Hungary otc pharmaceuticals market in 2017?
What factors are affecting the strength of competition in the Hungary otc pharmaceuticals market?
How has the market performed over the last five years?
Who are the top competitiors in Hungary's otc pharmaceuticals market?
OTC Pharmaceuticals in Hungary industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Hungary otc pharmaceuticals market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other analgesics), and medicated skin products (anti-bacteria’s, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2012 annual average exchange rates.
*The Hungarian OTC pharmaceuticals market had total revenues of $482.3m in 2012, representing a compound annual growth rate (CAGR) of 3.2% between 2008 and 2012.
*The traditional medicines segment was the market's most lucrative in 2012, with total revenues of $188.0m, equivalent to 39% of the market's overall value.
*The performance of the market is forecast to follow the similar pattern with an anticipated CARC of 3.2% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $565.5m by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the otc pharmaceuticals market in Hungary
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the otc pharmaceuticals market in Hungary
Leading company profiles reveal details of key otc pharmaceuticals market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Hungary otc pharmaceuticals market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the Hungary economy
Key Questions Answered
What was the size of the Hungary otc pharmaceuticals market by value in 2012?
What will be the size of the Hungary otc pharmaceuticals market in 2017?
What factors are affecting the strength of competition in the Hungary otc pharmaceuticals market?
How has the market performed over the last five years?
Who are the top competitiors in Hungary's otc pharmaceuticals market?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
Beres Pharmaceuticals, EGIS Pharmaceuticals Plc, Johnson & Johnson and Novartis AG
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Geography segmentation 2
Market share 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Geography segmentation 10
Market share 11
Market distribution 12
Market Outlook 13
Market value forecast 13
Five Forces Analysis 14
Summary 14
Buyer power 15
Supplier power 16
New entrants 17
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Beres Pharmaceuticals 20
EGIS Pharmaceuticals Plc 21
Johnson & Johnson 24
Novartis AG 27
Macroeconomic Indicators 31
Country Data 31
Appendix 33
Methodology 33
Industry associations 34
Related research 34
LIST OF TABLES
Table 1: Hungary OTC pharmaceuticals market value: $ million, 2008–12 8
Table 2: Hungary OTC pharmaceuticals market category segmentation: $ million, 2012 9
Table 3: Hungary OTC pharmaceuticals market geography segmentation: $ million, 2012 10
Table 4: Hungary OTC pharmaceuticals market share: % share, by value, 2012 11
Table 5: Hungary OTC pharmaceuticals market distribution: % share, by value, 2012 12
Table 6: Hungary OTC pharmaceuticals market value forecast: $ million, 2012–17 13
Table 7: Beres Pharmaceuticals : key facts 20
Table 8: EGIS Pharmaceuticals Plc: key facts 21
Table 9: EGIS Pharmaceuticals Plc: key financials ($) 22
Table 10: EGIS Pharmaceuticals Plc: key financials (HUF) 22
Table 11: EGIS Pharmaceuticals Plc: key financial ratios 22
Table 12: Johnson & Johnson: key facts 24
Table 13: Johnson & Johnson: key financials ($) 25
Table 14: Johnson & Johnson: key financial ratios 25
Table 15: Novartis AG: key facts 27
Table 16: Novartis AG: key financials ($) 28
Table 17: Novartis AG: key financial ratios 29
Table 18: Hungary size of population (million), 2008–12 31
Table 19: Hungary gdp (constant 2000 prices, $ billion), 2008–12 31
Table 20: Hungary gdp (current prices, $ billion), 2008–12 31
Table 21: Hungary inflation, 2008–12 32
Table 22: Hungary consumer price index (absolute), 2008–12 32
Table 23: Hungary exchange rate, 2008–12 32
LIST OF FIGURES
Figure 1: Hungary OTC pharmaceuticals market value: $ million, 2008–12 8
Figure 2: Hungary OTC pharmaceuticals market category segmentation: % share, by value, 2012 9
Figure 3: Hungary OTC pharmaceuticals market geography segmentation: % share, by value, 2012 10
Figure 4: Hungary OTC pharmaceuticals market share: % share, by value, 2012 11
Figure 5: Hungary OTC pharmaceuticals market distribution: % share, by value, 2012 12
Figure 6: Hungary OTC pharmaceuticals market value forecast: $ million, 2012–17 13
Figure 7: Forces driving competition in the OTC pharmaceuticals market in Hungary, 2012 14
Figure 8: Drivers of buyer power in the OTC pharmaceuticals market in Hungary, 2012 15
Figure 9: Drivers of supplier power in the OTC pharmaceuticals market in Hungary, 2012 16
Figure 10: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Hungary, 2012 17
Figure 11: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Hungary, 2012 18
Figure 12: Drivers of degree of rivalry in the OTC pharmaceuticals market in Hungary, 2012 19
Figure 13: EGIS Pharmaceuticals Plc: revenues & profitability 23
Figure 14: EGIS Pharmaceuticals Plc: assets & liabilities 23
Figure 15: Johnson & Johnson: revenues & profitability 25
Figure 16: Johnson & Johnson: assets & liabilities 26
Figure 17: Novartis AG: revenues & profitability 29
Figure 18: Novartis AG: assets & liabilities 30
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Geography segmentation 2
Market share 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Geography segmentation 10
Market share 11
Market distribution 12
Market Outlook 13
Market value forecast 13
Five Forces Analysis 14
Summary 14
Buyer power 15
Supplier power 16
New entrants 17
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Beres Pharmaceuticals 20
EGIS Pharmaceuticals Plc 21
Johnson & Johnson 24
Novartis AG 27
Macroeconomic Indicators 31
Country Data 31
Appendix 33
Methodology 33
Industry associations 34
Related research 34
LIST OF TABLES
Table 1: Hungary OTC pharmaceuticals market value: $ million, 2008–12 8
Table 2: Hungary OTC pharmaceuticals market category segmentation: $ million, 2012 9
Table 3: Hungary OTC pharmaceuticals market geography segmentation: $ million, 2012 10
Table 4: Hungary OTC pharmaceuticals market share: % share, by value, 2012 11
Table 5: Hungary OTC pharmaceuticals market distribution: % share, by value, 2012 12
Table 6: Hungary OTC pharmaceuticals market value forecast: $ million, 2012–17 13
Table 7: Beres Pharmaceuticals : key facts 20
Table 8: EGIS Pharmaceuticals Plc: key facts 21
Table 9: EGIS Pharmaceuticals Plc: key financials ($) 22
Table 10: EGIS Pharmaceuticals Plc: key financials (HUF) 22
Table 11: EGIS Pharmaceuticals Plc: key financial ratios 22
Table 12: Johnson & Johnson: key facts 24
Table 13: Johnson & Johnson: key financials ($) 25
Table 14: Johnson & Johnson: key financial ratios 25
Table 15: Novartis AG: key facts 27
Table 16: Novartis AG: key financials ($) 28
Table 17: Novartis AG: key financial ratios 29
Table 18: Hungary size of population (million), 2008–12 31
Table 19: Hungary gdp (constant 2000 prices, $ billion), 2008–12 31
Table 20: Hungary gdp (current prices, $ billion), 2008–12 31
Table 21: Hungary inflation, 2008–12 32
Table 22: Hungary consumer price index (absolute), 2008–12 32
Table 23: Hungary exchange rate, 2008–12 32
LIST OF FIGURES
Figure 1: Hungary OTC pharmaceuticals market value: $ million, 2008–12 8
Figure 2: Hungary OTC pharmaceuticals market category segmentation: % share, by value, 2012 9
Figure 3: Hungary OTC pharmaceuticals market geography segmentation: % share, by value, 2012 10
Figure 4: Hungary OTC pharmaceuticals market share: % share, by value, 2012 11
Figure 5: Hungary OTC pharmaceuticals market distribution: % share, by value, 2012 12
Figure 6: Hungary OTC pharmaceuticals market value forecast: $ million, 2012–17 13
Figure 7: Forces driving competition in the OTC pharmaceuticals market in Hungary, 2012 14
Figure 8: Drivers of buyer power in the OTC pharmaceuticals market in Hungary, 2012 15
Figure 9: Drivers of supplier power in the OTC pharmaceuticals market in Hungary, 2012 16
Figure 10: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Hungary, 2012 17
Figure 11: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Hungary, 2012 18
Figure 12: Drivers of degree of rivalry in the OTC pharmaceuticals market in Hungary, 2012 19
Figure 13: EGIS Pharmaceuticals Plc: revenues & profitability 23
Figure 14: EGIS Pharmaceuticals Plc: assets & liabilities 23
Figure 15: Johnson & Johnson: revenues & profitability 25
Figure 16: Johnson & Johnson: assets & liabilities 26
Figure 17: Novartis AG: revenues & profitability 29
Figure 18: Novartis AG: assets & liabilities 30
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.